Guest guest Posted December 1, 2004 Report Posted December 1, 2004 > Monday, November 29, 2004 commentary: >Scientific medical journals like JAMA fail basic credibility standards; >medical journals become increasingly irrelevant >http://www.newstarget.com/001890.html > >The Journal of the American Medical Association -- JAMA -- and other >scientific medical journals have been caught red-handed by the Center >for Science in the Public Interest for failing to disclose the financial >relationships between study authors and companies that might benefit >from such studies. For example, one author of a study published in JAMA >that conducted research on kidney disease did not disclose that he is a >consultant paid by Merck, Bristol-Meyers, Squibb, GlaxoSmithKline, and >Pfizer, all of which have products that could be marketed to the public >based on the information presented in the study. > >Here's how the con works: the study author receives cash from these >pharmaceutical companies, gets his study published in a prestigious >scientific journal, and then the drug companies can state that they are >basing the marketing of their product on published, peer-reviewed >scientific facts. The hidden fact in all of this, of course, is that the >author of the study is on the payroll of these companies and didn't even >bother to disclose that relationship to the journal. It's good old >fashioned corruption... but with the stamp of approval from so-called > " modern science. " > >It isn't just this one study, either -- a review of JAMA articles by the >CSPI revealed that 11.3% of the articles reviewed had non-disclosed >conflicts of interest. For a journal that claims to be presenting >scientific truth in a non-biased way that is independent of >pharmaceutical company influence, that's an alarmingly high number. And, >of course, it's one of the reasons why these scientific journals are >increasingly considered to be lacking in scientific credibility today. A >number of journals were caught in the same study, revealing that this >failure to disclose conflicts of interest is not merely something that >happens at the American Medical Association, but something that is >widespread in the conventional medical community. > >None of this comes as a surprise to me, since I've been one of the most >outspoken critics of scientific journals for many years. Too many of >these journals are masquerading as stewards of good science -- they >pretend to show articles that are well-researched, that are authored by >people who have no financial interest in their publication, and that >have been put through a rigorous quality control process known as peer >review. But in fact what you often find in these journals is the >exclusion of articles that talk about alternative therapies or >pioneering therapies that compete with pharmaceutical profits. You also >find a closed network of old school, closed-minded, conventional >researchers and medical doctors who primarily use the journals to >protect their own belief systems by only allowing the publication of >articles that agree with their narrow beliefs. In that regard, it's more >like a dogma or a religion than a scientific community. > >Often, the so-called scientific truth presented by these journals is >really just a relative truth that has been invented by a circle of >influential doctors, researchers and journal editors who define >scientific truth by choosing what to publish (and what to ignore). So, >it is a rather obvious case of circular reasoning on their side. In >other words, to put it more plainly, it's true if they say it is, and if >they reject a paper, then it's not true. Scientific fact is whatever >they tell you it should be. > >But that philosophy stands at odds with true science. True science is >based on a demonstrated curiosity about the way nature and the universe >works. A true scientist would look at the relationships between the >consumption of water and human health and they might ask, " What is the >role of water in the human body? " Or they might look at plants and >observe the miraculous nature of how plants are tiny pharmaceutical >factories that convert vitamins and minerals, sunlight, and carbon >dioxide into powerful medicinal compounds that can enhance human health. >True scientists would look at the nature of relationships and how people >who have more friends and engage in more social activities tend to live >healthier, longer lives than those who don't. Those are the kinds of >activities that true scientists pursue, because they are curious about >the way the world works and how human beings can take advantage of >natural laws in order to enhance their health and quality of life. > >But those aren't the kinds of topics that these so-called conventional >medical scientists pursue. They pursue topics like, " How do we cure >cancer with nanotechnology? " or " How do we override the body's immune >system and interfere with it using toxic chemicals that poison the >body? " They might say, " How do we take this patented drug that nobody >else can legally sell, and market it to the entire world by inventing a >disease, such as social anxiety disorder, and then sell the drug at >monopoly prices to people while confiscating imported generic versions >of that drug from another country? " Those are the kinds of activities >that many of today's conventional scientists, doctors and pharmaceutical >executives pursue, and it's all one big school of people who are >essentially serving their own interests while invoking -- in a >blasphemous way -- so-called " science. " > >The bottom line to all of this is that the game is up -- these journals >are starting to be exposed for their deceit and their lack of >open-mindedness, as well as their failure to disclose the financial ties >between authors and pharmaceutical companies that benefit from the >publication of authors' studies. > >And by the way, I almost forgot to mention that most of these scientific >journals are, in fact, supported by advertising funds from >pharmaceutical companies. So, you have a direct financial link from >pharmaceutical companies to these journals, such as the Journal of the >American Medical Association, and then you have the journals either >neglecting, or even perhaps suppressing the disclosure of financial ties >between authors of articles they publish and the very same >pharmaceutical companies that are writing checks to the journals. I'm >sure the American Medical Association realizes that publishing JAMA is a >highly profitable business activity. It generates a lot of money, and >one has to wonder about the priority of that money when you're standing >in front of the pharmaceutical executive who's handing you a check for >$100,000 or $1,000,000 (or some amount that's even larger). > >Personally, I don't trust any scientific publication that survives based >on advertising revenues from pharmaceutical companies. The conflict of >interest is so obvious as to be utterly ridiculous -- the journals need >to keep their financial lifelines alive, and that means supporting >pharmaceutical companies that keep on sending them checks. In that kind >of system, there is no such thing as credibility. You can't have an >unbiased publication of any kind if you're dependent on advertising >revenues paid directly to you by the very same companies you're supposed >to be covering in the editorial content. These medical journals are, >effectively, bought out by the financial interests of Big Pharma. > >And, by the way, the whole concept of a medical journal is increasingly >irrelevant these days anyway. Thanks to the internet and the launching >of an open-source medical journal endeavor, we all have the capacity to >participate in open databases of clinical studies. We don't need to be >reading niche journals that are financed by pharmaceutical companies and >still charge readers hundreds or thousands of dollars a year for access >to their articles. What we need in this country is open, public access >to all of the trials and studies that are being conducted, and we need a >more open-minded, web-based journal system, where pioneering researchers >and those who are engaged in activities outside conventional medicine >can get solid, scientific work published, regardless of whether it >threatens the profits of drug companies. > > >About the author: >Author Mike Adams is a holistic nutritionist with over 4,000 hours of >study on nutrition, wellness, food toxicology and the true causes of >disease and health. He is well versed on nutritional and lifestyle >therapies for weight loss and disease prevention / reversal. View Adams' >health statistics showing LDL cholesterol of 67 and outstanding blood >chemistry. Adams uses no prescription drugs whatsoever and relies >exclusively on natural health, nutrition and exercise to achieve optimum >health. Adams' books include the Seven Laws of Nutrition, The Five Soft >Drink Monsters and Superfoods For Optimum Health. In his spare time, >Adams engages in pilates, cycling, strength training, gymnastics and >comedy improv training. In the technology industry, Adams is president >and CEO of a well known email marketing software company. > >Related Reading: > >* Several leading medical and science journals fail to enforce their own >policies for disclosing financial conflicts of interest among >contributing authors, according to a study released today by the >nonprofit Center for Science in the Public Interest (CSPI). >* It identified at least 13 articles where authors did not disclose >relevant conflicts of interest that should have been disclosed according >to the journals' policies. >* a Procter & Gamble scientist, William Owens, was only identified in >EHP as an official of the Organization for Economic Co-operation and >Development in an article that validated a toxicity test that would >likely be used on various P & G products. >* a National Institutes of Health senior scientist published a study in >JAMA on predictors of kidney disease, but did not disclose his >consulting relationships with Merck, Bristol-Myers Squibb, >GlaxoSmithKline, and Pfizer, all of which sell products whose marketing >could benefit from the insights gleaned from that study. >* Nondisclosure of financial conflicts of interest was a problem at all >four journals, but JAMA had the highest rate of nondisclosure of >conflicts at 11.3 percent (six out of 53 articles). >* CSPI recommends that journal editors require authors to disclose any >financial arrangements they have had with private firms within the past >three years, regardless of whether those arrangements relate to the >subject of the article, and that the conflicts be published if they are >in any way related to the article's subject. >* CSPI also says that authors should be required to disclose any patent >applications, or intentions to apply for any patents. >* " Some of the blame for the failure to disclose these conflicts rests >with the individual scientists, who clearly feel comfortable withholding >fairly glaring conflicts, " Goozner said. > > >========================================== >Source: http://cspinet.org/new/200407123.html >Report Faults Scientific Journals on Financial Disclosure >** >July 12, 2004 > >CSPI Says Authors Fail to Disclose Financial Conflicts of Interest; >Journals Fail to Enforce Disclosure Policies > >Several leading medical and science journals fail to enforce their own >policies for disclosing financial conflicts of interest among >contributing authors, according to a study released today by the >nonprofit Center for Science in the Public Interest (CSPI). The study >examined 163 articles in the New England Journal of Medicine (NEJM), the >Journal of the American Medical Association (JAMA), Environmental Health >Perspectives (EHP), and Toxicology and Applied Pharmacology (TAP). It >identified at least 13 articles where authors did not disclose relevant >conflicts of interest that should have been disclosed according to the >journals’ policies. CSPI found another 11 articles where there were >undisclosed conflicts of interest that might not have directly related >to the subject at hand, but should have been disclosed nevertheless. > >Some of the unpublished conflicts of interest include: > >* a University of Arkansas College of Medicine professor, Dr. John >Shaughnessy, published a NEJM article outlining the potential efficacy >of a treatment for multiple myeloma, but did not disclose that he >intended to apply for a patent on the underlying technology. He also >failed to disclose that he is a paid consultant for drug companies >developing vaccines for the condition. > >* a Procter & Gamble scientist, William Owens, was only identified in >EHP as an official of the Organization for Economic Co-operation and >Development in an article that validated a toxicity test that would >likely be used on various P & G products. There was no disclosure of >Owens’ employment with Procter & Gamble in this article, even though it >was known to EHP editors. > >* two scientists at the U.S. Armed Forces Institute of Pathology, Frank >D. Kolodgie and Renu Virmani, published an article in NEJM about the >formation of plaque in coronary arteries, but did not disclose their >consulting relationships with over 20 companies in the heart disease >treatment field, including Medtronic, Guidant, Boston Scientific, and >Novartis. > >* a National Institutes of Health senior scientist published a study in >JAMA on predictors of kidney disease, but did not disclose his >consulting relationships with Merck, Bristol-Myers Squibb, >GlaxoSmithKline, and Pfizer, all of which sell products whose marketing >could benefit from the insights gleaned from that study. > >“Published research that fails to disclose authors’ ties to drug >companies threatens the credibility of scientific journals and rightly >undermines public confidence in studies about the safety or efficacy of >various drugs or chemicals,” said Merrill Goozner, director of the >Integrity in Science Project at CSPI and the author of the study. > >Nondisclosure of financial conflicts of interest was a problem at all >four journals, but JAMA had the highest rate of nondisclosure of >conflicts at 11.3 percent (six out of 53 articles). The undisclosed >conflicts in JAMA ranged from consulting fees from companies immediately >involved in the subject of the study to authors holding patents on >technologies that may one day prove valuable because of information >contained in the study. EHP had a nondisclosure rate of 8.6 percent >(three of 35 articles), TAP had a nondisclosure rate of 6.1 percent (two >of 33 articles), and NEJM had the lowest rate of nondisclosure at 4.8 >percent (two of 42 studies examined). CSPI typically researched only the >first and last of the authors cited for each article, and only when no >disclosure statement was published for either author, so there are >likely to be undisclosed conflicts among the other authors not researched. > >CSPI recommends that journal editors require authors to disclose any >financial arrangements they have had with private firms within the past >three years, regardless of whether those arrangements relate to the >subject of the article, and that the conflicts be published if they are >in any way related to the article’s subject. CSPI also says that authors >should be required to disclose any patent applications, or intentions to >apply for any patents. To encourage authors to comply with journals’ >policies, CSPI also recommends that editors adopt strong sanctions for >failing to disclose conflicts of interest, such as a three-year ban on >publication imposed on authors who fail to make complete disclosures. > >“Some of the blame for the failure to disclose these conflicts rests >with the individual scientists, who clearly feel comfortable withholding >fairly glaring conflicts,” Goozner said. “But much of the blame must >rest with the journal editors themselves, who, for the most part, have >created disclosure policies that too narrowly define what conflicts are >relevant.” > > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.